Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

82
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
82
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

172
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
172
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

146
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
146
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
  1. Home
  3. Research Domains
  5. Health Sciences
  7. Epidemiology
  9. Major Global Burdens Of Disease
  11. Investigating The Impact Of Social Determinants Of Health On Diagnostic Delays And Access To Antifibrotic Treatment In Idiopathic Pulmonary Fibrosis

Investigating the Impact of Social Determinants of Health on Diagnostic Delays and Access to Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis

Rui Li1, Qiuhao Lu1, Andrew Wen1

  • 1McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|June 12, 2025

Related Experiment Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.8K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

260
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

93

View abstract on PubMed

Summary
This summary is machine-generated.

Social determinants of health impact idiopathic pulmonary fibrosis (IPF) diagnosis and treatment. Higher education and insurance accelerate IPF diagnosis, while insurance, gender, and race influence antifibrotic treatment access.

Area of Science:

  • Pulmonary Medicine
  • Health Disparities Research
  • Social Epidemiology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a rare, progressive lung disease with diagnostic and treatment challenges.
  • Patients often experience significant delays in diagnosis and limited access to antifibrotic therapies.
  • Social determinants of health (SDoH) are increasingly recognized as critical factors influencing health outcomes.

Purpose of the Study:

  • To investigate the association between SDoH and time to IPF diagnosis.
  • To examine the relationship between SDoH and receipt of antifibrotic treatment in IPF patients.

Main Methods:

  • Utilized zip code-level demographic data from the American Community Survey to approximate SDoH.
  • Employed logistic regression and XGBoost classification models to analyze SDoH associations.

Related Experiment Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.8K
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

260
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

93
  • Focused on two key outcomes: time from symptom onset to IPF diagnosis and antifibrotic treatment receipt.

    • Main Results:

    • For diagnosis time, education, gender, and insurance were top SDoH factors; higher education and insurance correlated with faster diagnosis, males diagnosed quicker than females.
    • For antifibrotic treatment, insurance, gender, and race were key SDoH factors; better insurance, male gender, and White race were associated with higher treatment rates.
    • Identified specific SDoH influencing diagnostic delays and treatment access in IPF.

    Conclusions:

    • SDoH significantly impact the timeliness of IPF diagnosis and access to antifibrotic therapies.
    • Disparities exist in IPF care influenced by socioeconomic factors like education, insurance, gender, and race.
    • Findings highlight the need to address SDoH to reduce inequities in IPF diagnosis and treatment.